Approval of Libervant marks the first orally administered rescue medication for this age group to be cleared by the FDA for epilepsy.

Hercessi marks Accord BioPharma’s first biosimilar to be approved in the United States, with multiple indications for HER2-overexpressing breast and gastric cancers.

Blankenship, vice president of policy initiatives and advocacy at The Academy of Nutrition and Dietetics, discusses how AOMs can play a role in creating strategies to manage the obesity epidemic.

In this Pharmaceutical Executive video interview, Kalim Saliba, Chief Product Officer, Dotmatics discusses their Luma platform, Luma Lab Connect, and what this technology could mean for industry.

The lawsuit, filed the department of labor, alleges that Blue Cross improperly collected provider taxes from self-funded employer health plans.

The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a look at the organization's pipeline.

Approval update comes as a result of findings from Study 5310, which addressed Biktarvy’s pharmacokinetics, safety, and efficacy during pregnancy and postpartum periods in patients with HIV.

Beqvez, a one-time gene therapy, offers hope to patients with moderate to severe hemophilia B who use regular factor IX prophylaxis, suffer severe hemorrhages, or recurrent serious bleeding.

In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses what other tactics healthcare marketers can utilize to connect with diverse audiences on a deeper level

The latest news for pharma industry insiders.

PanOmiQ is referred to as the fasted technology of its kind by the company.

Melton, VP of scientific operations and development at Slope, discusses how new technologies can be used to ensure data is accurate.

The center will offer local residents with opportunities and training to enter the pharmacy work force.

Companies reported that the new formulation of Coartem met required pharmacokinetic profiles and displayed promising efficacy and safety treating malaria in infants.

Pivya has shown efficacy against bacteria strains such as Escherichia coli, Proteus mirabilis, and Staphylococcus saprophyticus.

Sanders wrote a letter to Novo Nordisk announcing the investigation.

In this Pharmaceutical Executive video interview, Amanda Powers-Han, Chief Marketing Officer, Greater Than One, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but address their specific healthcare needs

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics, provides a look into the potential of further indications for Coya 302 amid promising ALS study.

AI allows patients, doctors, and payers to make informed decisions based on evidence at a much faster pace.

The latest news for pharma industry insiders.

In an interview with Pharm Exec Associate Editor Don Tracy, Howard Berman, Chairman, CEO, Coya Therapeutics offers a preview on what the nexts steps are after presenting positive data on Coya 302 for the treatment of ALS.

Company aims to provide affordable emergency treatment from overdoses of heroin, fentanyl, and prescription opioids.

In this Pharmaceutical Executive video interview, Jon Hamrick, Partner, Curatio Scientia Advisors and Jon Rawlson, President & Founder, Armory Hill Advocates, speak about what kind of impact their survey's findings impact will be on the industry.